Literature DB >> 15862278

A homology model for human alpha-l-iduronidase: insights into human disease.

Brian P Rempel1, Lorne A Clarke, Stephen G Withers.   

Abstract

Genotype-phenotype correlations in genetic diseases for which missense mutations lead to disease remain a challenge. This is particularly true for diseases caused by alterations of proteins for which no three-dimensional structure is available. One such disease is Mucopolysaccharidosis type I, a disorder arising from a lack of activity of the lysosomal enzyme alpha-l-iduronidase (IDUA, EC 3.2.1.76). This deficiency compromises the degradation pathway of glycosaminoglycans such as heparan sulfate and dermatan sulfate, leading to substrate accumulation, which ultimately results in a multisystem disorder. Patients with IDUA deficiency have a wide spectrum of disease ranging from an early onset, rapidly progressive form leading to death in the first decade of life, to an attenuated disease which manifests in adolescence and leads to progressive joint and cardiac disease but is associated with a normal life span. Many patients fit into a disease phenotype intermediate to these extremes. While a number of point mutations have been described as leading to varying degrees of disease severity, a structural basis for these genotype-phenotype correlations has not been available owing to the lack of a three-dimensional structure for IDUA. A homology model for the IDUA enzyme was constructed based on the recently solved crystal structure of the beta-xylosidase from Thermoanaerobacterium saccharolyticum (XyTS, EC 3.2.1.37), both of which belong to the same sequence-related family (CAZY family 39). This model provides insights into why certain point mutations produce severely misfolded proteins and thus lead to severe disease, and why other mutations produce proteins with only minor structural perturbations and therefore the attenuated form of the disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15862278     DOI: 10.1016/j.ymgme.2004.12.006

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  11 in total

1.  The thyroid hormone-inactivating deiodinase functions as a homodimer.

Authors:  G D Vivek Sagar; Balázs Gereben; Isabelle Callebaut; Jean-Paul Mornon; Anikó Zeöld; Cyntia Curcio-Morelli; John W Harney; Cristina Luongo; Michelle A Mulcahey; P Reed Larsen; Stephen A Huang; Antonio C Bianco
Journal:  Mol Endocrinol       Date:  2008-03-20

2.  Crystallization, X-ray diffraction analysis and SIRAS phasing of human α-L-iduronidase.

Authors:  Nobuo Maita; Hisaaki Taniguchi; Hitoshi Sakuraba
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-10-30

3.  Human α-L-iduronidase uses its own N-glycan as a substrate-binding and catalytic module.

Authors:  Nobuo Maita; Takahiro Tsukimura; Takako Taniguchi; Seiji Saito; Kazuki Ohno; Hisaaki Taniguchi; Hitoshi Sakuraba
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-19       Impact factor: 11.205

4.  Structural study on mutant alpha-L-iduronidases: insight into mucopolysaccharidosis type I.

Authors:  Kanako Sugawara; Seiji Saito; Kazuki Ohno; Torayuki Okuyama; Hitoshi Sakuraba
Journal:  J Hum Genet       Date:  2008-03-14       Impact factor: 3.172

5.  Structural and mechanistic insight into the basis of mucopolysaccharidosis IIIB.

Authors:  Elizabeth Ficko-Blean; Keith A Stubbs; Oksana Nemirovsky; David J Vocadlo; Alisdair B Boraston
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-28       Impact factor: 11.205

6.  Laronidase-functionalized multiple-wall lipid-core nanocapsules: promising formulation for a more effective treatment of mucopolysaccharidosis type I.

Authors:  Fabiana Quoos Mayer; Márcia Duarte Adorne; Eduardo André Bender; Talita Giacomet de Carvalho; Anna Cláudia Dilda; Ruy Carlos Ruver Beck; Sílvia Stanisçuaski Guterres; Roberto Giugliani; Ursula Matte; Adriana Raffin Pohlmann
Journal:  Pharm Res       Date:  2014-09-11       Impact factor: 4.200

7.  Mucopolysaccharidosis type I: molecular characteristics of two novel alpha-L-iduronidase mutations in Tunisian patients.

Authors:  Latifa Chkioua; Souhir Khedhiri; Hadhami Ben Turkia; Rémy Tcheng; Roseline Froissart; Henda Chahed; Salima Ferchichi; Marie Françoise Ben Dridi; Christine Vianey-Saban; Sandrine Laradi; Abdelhedi Miled
Journal:  Diagn Pathol       Date:  2011-06-03       Impact factor: 2.644

8.  Insights into mucopolysaccharidosis I from the structure and action of α-L-iduronidase.

Authors:  Haiying Bie; Jiang Yin; Xu He; Allison R Kermode; Ethan D Goddard-Borger; Stephen G Withers; Michael N G James
Journal:  Nat Chem Biol       Date:  2013-09-11       Impact factor: 15.040

9.  alpha-L-iduronidase therapy for mucopolysaccharidosis type I.

Authors:  Jakub Tolar; Paul J Orchard
Journal:  Biologics       Date:  2008-12

10.  Mucopolysaccharidosis type I in 21 Czech and Slovak patients: mutation analysis suggests a functional importance of C-terminus of the IDUA protein.

Authors:  Alzbeta Vazna; Clare Beesley; Linda Berna; Larisa Stolnaja; Helena Myskova; Michaela Bouckova; Hana Vlaskova; Helena Poupetova; Jiri Zeman; Martin Magner; Anna Hlavata; Bryan Winchester; Martin Hrebicek; Lenka Dvorakova
Journal:  Am J Med Genet A       Date:  2009-05       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.